EURL ECVAM (the European Union Reference Laboratory for Alternatives to Animal Testing) has released a strategy to reduce, replace, and refine the use of animals in the assessment of acute mammalian systemic toxicity. The EURL ECVAM strategy highlights the importance of developing adverse outcome pathways (AOPs) and integrated approaches to testing and assessment (IATA) related to acute toxicity. It also discusses improvements in the predictability of the 3T3 NRU assay, development of additional in vitro and in silico approaches, waiving acute toxicity testing based on repeated dose data, refinement of in vivo studies, and provides a framework for prioritizing the alternative methods that have been submitted to EURL ECVAM for validation. Click here for more information and to download a copy of the strategy.